UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO SECTION 13A-16 OR 15D-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of ~~February~~March 2026

Commission File Number: 001-41316

Alpha Tau Medical Ltd.

(Exact Name of Registrant as Specified in Its Charter)

Kiryat HaMada St. 5

Jerusalem, Israel 9777605

+972 (3) 577-4115

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

CONTENTS

On ~~February~~March 249, 2026, Alpha Tau Medical Ltd. (the “Company”) issued a press release titled “Alpha Tau ~~Medical~~Announces ~~Receives~~Full ~~Japanese~~Year ~~Marketing~~2025 ~~Approval~~Financial ~~for~~Results ~~Alpha DaRT® in Unresectable Locally Advanced or Locally Recurrent Head~~ and ~~Neck~~Provides ~~Cancer~~Corporate Update.” A copy of this press release is attached to this Form 6-K as Exhibit 99.1.

~~The~~This ~~information in this~~ Report ~~on Form 6-K, including Exhibit 99.1 attached hereto, is being furnished~~ and ~~shall not be deemed “filed” for~~ the ~~purposes~~related ofexhibits ~~Section~~are ~~18 of the Securities~~incorporated ~~Exchange~~by ~~Act~~reference ofinto ~~1934, as amended (~~the ~~“Exchange~~registrant’s ~~Act”),~~Registration orStatements ~~otherwise~~on ~~subject~~Form toF-3 ~~the~~(File ~~liabilities~~Nos. ~~of that Section~~333-271073, 333-264306, ~~nor shall~~333-274457 itand be333-288240) ~~deemed~~and ~~incorporated~~Form byS-8 (File ~~reference~~Nos. ~~in any filing made by the Company under the Securities Act of 1933~~333-264169, ~~as amended~~333-270406, ~~or the Exchange~~ ~~Act,~~333-277733 ~~except~~and ~~as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing~~333-285745).

EXHIBIT INDEX

Exhibit No.		Description
99.1		Press ~~release~~Release dated ~~February~~March 249, 2026.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Alpha Tau Medical Ltd.
Date: February 24, 2026	By:	/s/ Uzi Sofer
Date: March 9, 2026	By:	/s/ Uzi Sofer
		Uzi Sofer
		Chief Executive Officer

Filing Compare · Alpha Tau Medical Ltd.